Researches of the assortment of drugs for the treatment of diabetes II type оn the pharmaceutical market of Ukraine

Keywords: Diabetes mellitus, assortment, pharmaceutical market, analysis

Abstract

Type II diabetes is a global pandemic, as evidenced by data from a study by the International Diabetes Federation. The disease is a chronic, progressive process with a special metabolic condition that is characterized by hyperglycemia. Therapeutic effects should be aimed at eliminating the main causes of type II diabetes mellitus: insulin secretion dysfunction, a decrease in tissue resistance to insulin, or a combination of these. The aim of the work was to study the range of oral antidiabetic drugs on the pharmaceutical market of Ukraine for the treatment of type II diabetes. The objects of study were drugs used in the treatment of type II diabetes. Studies were conducted using content analysis of official sources of information. In the course of the work, the range of antidiabetic drugs, classification, mechanism of action, cost, main advantages and disadvantages of use were established. It is established that the most common dosage form for the treatment of diabetes are tablets, which occupy more than 90% of the total range of drugs. The lack of modern types of dosage forms in the group A10B is the basis for the creation of new drugs with improved biopharmaceutical and consumer properties.

The data obtained indicate a strong dependence of the pharmaceutical market of antidiabetic drugs of Ukraine on imports, with the exception of insulin (А10В). The share of imports in the market in quantitative terms for the period under review amounted to more than 75.86% of the total market volume.

It has been established that the use of drugs of the A10B A, A10B F groups with an affordable cost with active therapy contributes to a lower rate of development of diabetes mellitus type II and a high degree of regression to normal glucose, without affecting the fluctuations in body weight. Preparations of the new generation (A10B H, A10B J, A10B X) are highly effective with an insufficient safety profile. The high cost of drugs of these groups makes them inaccessible to the general population. It has been shown that only metformin and voglibosis have a positive effect on body mass fluctuation rates, which will ensure safe and effective glycemic control with minimal risk of hypoglycemia and without weight gain in the treatment of type II diabetes.

References

1. Hlobalnуi doklad po dyabetu [Elektronnyi resurs] // International Diabetes Federation. – 2016. –http://apps.who.int/iris/bitstream/handle/10665/275388/9789244565254-rus.pdf?ua=1

2. Tkachenko V. I., Vydyborets N. V., Kovalenko O. F. Analiz poshyrenosti ta zakhvoriuvanosti na tsukrovyi diabet i yoho uskladnennia sered naselennia Ukrainy ta u Kyivskii oblasti za 2004–2013 rr. Zdobutky klinichnoi i eksperymentalnoi medytsyny. – 2014. – № 2. ‒ S. 177–182.

3. Tsukrovyi diabet [Elektronnyi resurs] // Empendium. – 2016. https://empendium.com/ua/chapter/B27.II.13.1

4. Pankiv V. (2018) Novi rekomendatsii Amerykanskoi diabetychnoi asotsiatsii 2018 roku z diahnostyky ta likuvannia tsukrovoho diabetu // Mizhnarodnyi endokrynolohichnyi zhurnal.

5. Unifikovanyi klinichnyi protokol pervynnoi ta vtorynnoi (spetsializovanoi) medychnoi dopomohy pry tsukrovomu diabeti 2 typu, zatverdzhenyi nakazom Ministerstva okhorony zdorovia Ukrainy vid 21.12.2012 № 1118

6. Petunyna N. (2012) Preparatу sulfonylmochevynу v sovremennуkh alhorytmakh vedenyia bolnуkh sakharnуm dyabetom 2 typa у Еffektyvnaia farmakoterapyia // Еndokrynolohyia.

7. Dedova Y. Y., Shestakovoi M. V. (2011) Sakharnу dyabet: dyahnostyka, lechenye, profylaktyka. Medytsynskoe ynformatsyonnoe ahentstvo, 808.

8. Spravochnik «Kompendium. Likarski preparaty http://umedp.ru/articles/preparaty_sulfonilmocheviny_v_sovremennykh_algoritmakh_vedeniya_bolnykh_sakharnym_diabetom_2_tipa.html

9. Nemchenko A. S., Toraiev K. N., Nazarkina V. M. Analiz rynku antydiabetychnykh likarskykh zasobiv na osnovi metforminu // Sotsialna farmatsiia v okhoroni zdorovia. – 2018. – N 1. – S. 60–71.

10. Kravchun N. A., Kozakov A. V., Karachentsev Yu. Y. Sakharnуi dyabet 2 typa: skrynynh y faktorу ryska. – Novoe slovo, 2010. – 256 s.

11. Chaudhury A., Duvoor C., Dendi R. et al. Clinical review of antidiabetic drugs: Implications for type 2 diabetes mellitus management // Frontiers in endocrinology. – 2017. – N 8. – P. 6.

12. Nyenwe E. A., Jerkins T. W., Umpierrez G. E., Kitabchi A. E. Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes // Metabolism. – 2011. – V. 60 (1). – P. 1–23.

13. Reiestr optovo-vidpusknykh tsin na likarski zasoby [Elektronnyi resurs]. – Rezhym dostupu: http://moz.gov.ua/reestr-optovo-vidpusknih-cin-na-likarski-zasobi

14. Hollander P. Anti-diabetes and anti-obesity medications: effects on weight in people with diabetes // Diabetes Spectrum. – 2007. – V. 20 (3). – P. 159–165.

15. Ivko T., Germanyuk T. Rational choice of monotherapy for the treatment of type 2 diabetes mellitus based on the pharmacoeconomical analysis // Science Rise. – 2014. – N 4 (5). – P. 69–72.

16. Derzhavnyi reiestr likarskykh zasobiv Ukrainy [Elektronnyi resurs] – Rezhym dostupu: http://www.drlz.com.ua/

17. Ivko T. I., Hermaniuk T. A. Vyznachennia vartisno-efektyvnykh perevah skhem terapii tsukrovoho diabetu 2 typu iz zastosuvanniam suchasnykh inhibitoriv DPP-4 // Farmatsevtychnyi zhurnal. – 2014. – N 6. – S. 29.

18. Hermaniuk T. A., Ivko T. I., Bobruk V. P. Dynamika dostupnosti likarskykh zasobiv dlia monoterapii tsukrovoho diabetu 2 typu v Ukraini // Farmatsevtychnyi zhurnal. – 2017. – N 1. – S. 37–42.

19. Ivko T. I., Hermaniuk T. A. Vartisno-korysnyi analiz kombinovanoi terapii tsukrovoho diabetu 2 typu iz zastosuvanniam analizu chutlyvosti // Acta medica Leopoliensia. – 2015. – V. 21,N 1. – P. 61–65.

20. Neborachko M., Pkhakadze A., Vlasenko I. Current trends of digital solutions for diabetes management // Diabetes & Metabolic Syndrome: Clinical Research & Reviews. – 2018. – V. 12, Issue 4.
Published
2019-05-10
How to Cite
Kovalevska, I. V., Ruban, O. A., & Yevtushenko, O. M. (2019). Researches of the assortment of drugs for the treatment of diabetes II type оn the pharmaceutical market of Ukraine. Farmatsevtychnyi Zhurnal, (2), 13-23. https://doi.org/10.32352/0367-3057.2.19.02
Section
Management of pharmacy